In mild SMA models, notable gains in muscle mass and functional ability were demonstrated after recent developments in gene therapy employing AAV vectors to carry soluble ActRIIB or myostatin pro-peptides resistant to proteolytic activation [100,101]. Here, MSTN is linked to proximal spinal muscular atrophy.